Factors associated with a strictly undetectable viral load in HIV‐1‐infected patients
Open Access
- 21 March 2012
- journal article
- research article
- Published by Wiley in HIV Medicine
- Vol. 13 (9) , 568-573
Abstract
Objectives The aim of the study was to identify factors associated with a strictly undetectable viral load (VL) using a routine sensitive real‐time polymerase chain reaction (RT‐PCR) technology. Methods From a large prospective cohort, 1392 patients with a VL < 50 HIV‐1 RNA copies/mL while receiving a three‐drug suppressive regimen for at least 1 year were included in a cross‐sectional analysis. Patients were classified into three groups and compared by univariate and multivariate analysis: 479 patients with a strictly undetectable VL (group 1; 34%), 617 patients with detectable VL below the threshold of 20 copies/mL (group 2; 44%), and 296 patients with a VL of 20–50 copies/mL (group 3; 12%). Results Comparing groups 1 and 2, VL zenith < 5 log10 copies/mL [odds ratio (OR) 1.51; 95% confidence interval (CI) 1.15–1.99; P = 0.003], current CD4 T‐cell count < 500 cells/μL (OR 1.44; 95% CI 1.08–1.92; P = 0.01), and duration of viral suppression < 50 copies/mL longer than 2 years (OR 2.32; 95% CI 1.20–4.54; P = 0.01) were associated with undetectable VL. Comparing groups 1 and 3, VL zenith < 5 log10 copies/mL (OR 2.48; 95% CI 1.75–3.50; P < 0.001), duration of viral suppression < 50 copies/mL longer than 1 year (OR 3.33; 95% CI 1.66–6.66; P = 0.0006), and nonnucleoside reverse transcriptase inhibitor (NNRTI)‐based regimens (OR 1.45; 95% CI 1.03–2.04; P = 0.03) were associated with undetectable VL. No individual drug effect was found within NNRTI molecules. Conclusions Longer duration of viral suppression < 50 copies/mL, lower viral load zenith and NNRTI‐based regimen were independently associated with a strictly undetectable viral load. This routinely used RT‐PCR assay may prove to be a valuable tool in further large‐scale studies.Keywords
This publication has 20 references indexed in Scilit:
- Hide and Seek… Can We Eradicate HIV by Treatment Intensification?The Journal of Infectious Diseases, 2011
- Higher efficacy of nevirapine than efavirenz to achieve HIV-1 plasma viral load below 1 copy/mlAIDS, 2011
- The Effect of Raltegravir Intensification on Low-level Residual Viremia in HIV-Infected Patients on Antiretroviral Therapy: A Randomized Controlled TrialPLOS Medicine, 2010
- Myocardial infarction risk in HIV-infected patients: epidemiology, pathogenesis, and clinical managementAIDS, 2010
- HIV-1 Residual Viremia Correlates with Persistent T-Cell Activation in Poor Immunological Responders to Combination Antiretroviral TherapyPLOS ONE, 2009
- Genital Tract, Cord Blood, and Amniotic Fluid Exposures of Seven Antiretroviral Drugs during and after Pregnancy in Human Immunodeficiency Virus Type 1-Infected WomenAntimicrobial Agents and Chemotherapy, 2009
- Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapyProceedings of the National Academy of Sciences, 2008
- Episodes of low-level viral rebound in HIV-infected patients on antiretroviral therapy: frequency, predictors and outcomeJournal of Antimicrobial Chemotherapy, 2008
- Efficacy of Cerebrospinal Fluid (CSF)–Penetrating Antiretroviral Drugs against HIV in the Neurological Compartment: Different Patterns of Phenotypic Resistance in CSF and PlasmaClinical Infectious Diseases, 2005
- The neuropathogenesis of AIDSNature Reviews Immunology, 2005